Clinical Trial Update: FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of FR901228 (romidepsin) in relapsed or refractory non-Hodgkin's lymphoma was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• FR901228 (romidepsin) (romidepsin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2012-08-22